AFM13, a bi-specific engager-binding CD16 on NK cells, and CD30 on leukemia or lymphoma targets, exhibit enhanced killing of CD30+ tumor cells, leading to CAR-like responses (NCT03192202). This evidence concerns the gene FCGR3A and lymphoma.